当前位置: 首页 > 期刊 > 《上海医药》 > 202020
编号:13827886
五种人新型冠状病毒研究进展(5)
http://www.100md.com 2020年7月15日 《上海医药》 202020
     [25] Ying T, Du L, Ju TW, et al. Exceptionally potent neutralization of Middle East respiratory syndrome corona virus by human monoclonal antibodies[J]. J Virol, 2014, 88(14): 7796-7805.

    [26] Chen Z, Bao L, Chen C, et al. Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset[J]. J Infect Dis, 2017, 215(12): 1807-1815.

    [27] Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J]. SCI China Life Sci, 2020, 63(3): 457-460.

    [28] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8): 727-733.

    [29] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China[J]. JAMA, 2020 Feb 24. doi: 10.1001/ jama.2020.2648.

    [30] Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States[J]. N Engl J Med, 2020, 382(10): 929-936., 百拇医药(陈荔萍 周峰)
上一页1 2 3 4 5